Related Experiment Video
Updated: Mar 16, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
Nishitha Thumallapally1, Hana Yu1, Divya Asti1
1Department of Internal Medicine.
Abstract:
The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy difficult to derive. Despite the hurdles in current research, progress is underway toward more targeted therapeutic approaches. Several new drugs with novel mechanism of action and less toxic profile have been developed in the past decade, with the potential for use as single agents or in synergy with other treatment modalities in MM therapy. As our discovery of these emerging therapies progresses, so too does our need to reshape our knowledge on knowing how to apply them. This review highlights some of the recent landmark changes in MM management with specific emphasis on salvage drugs available for relapsed and refractory MM and also discusses some of the upcoming cutting-edge therapies that are currently in various stages of clinical development.
Insights
The treatment of multiple myeloma (MM) is advancing with new targeted therapies for relapsed and refractory patients. This review covers current salvage drugs and emerging treatments for MM management.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- The treatment landscape for multiple myeloma (MM) is rapidly evolving.
- Patient heterogeneity poses challenges in evaluating salvage therapy efficacy.
- Understanding MM pathophysiology drives the development of targeted treatments.
Purpose of the Study:
- To review recent advancements in MM management.
- To emphasize salvage drugs for relapsed and refractory MM.
- To discuss emerging therapies in clinical development for MM.
Main Methods:
- Literature review of landmark changes in MM management.
- Focus on salvage drugs for relapsed and refractory MM.
- Analysis of cutting-edge therapies in clinical development.
Main Results:
- Several new drugs with novel mechanisms and improved toxicity profiles have been developed.
- These agents show potential as single agents or in combination therapy for MM.
- Progress in understanding MM pathophysiology facilitates targeted therapeutic approaches.
Conclusions:
- The evolving understanding of MM necessitates updated knowledge on treatment application.
- Emerging therapies offer new hope for patients with relapsed and refractory MM.
- Continued research into novel agents and treatment strategies is crucial for improving MM outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...